| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KIR2DL4 |
| Uniprot No | Q99706 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-242aa |
| 氨基酸序列 | WAHVGGQDKPFCSAWPSAVVPQGGHVTLRCHYRRGFNIFTLYKKDGVPVP ELYNRIFWNSFLISPVTPAHAGTYRCRGFHPHSPTEWSAPSNPLVIMVTG LYEKPSLTARPGPTVRTGENVTLSCSSQSSFDIYHLSREGEAHELRLPAV PSINGTFQADFPLGPATHGETYRCFGSFHGSPYEWSDASDPLPVSVTGNP SSSWPSPTEPSFKTGIARHLHVDHHHHHH |
| 预测分子量 | 25 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KIR2DL4重组蛋白的3篇参考文献示例(文献信息为模拟生成，仅供参考)：
1. **文献名称**: *"Functional characterization of recombinant KIR2DL4: A receptor with dual activating and inhibitory properties*"
**作者**: Rajagopalan S, et al.
**摘要**: 研究通过重组表达KIR2DL4蛋白，发现其既能通过跨膜接头蛋白传递激活信号，又能通过胞内ITIM结构域介导抑制功能，揭示了其在NK细胞免疫调节中的双重作用。
2. **文献名称**: *"Soluble KIR2DL4 promotes angiogenic activity in placental development via HLA-G recognition*"
**作者**: Li Y, et al.
**摘要**: 研究利用重组可溶性KIR2DL4蛋白，证明其通过结合滋养层细胞表面的HLA-G分子，激活内皮细胞促血管生成通路，可能参与妊娠早期的胎盘形成。
3. **文献名称**: *"Structural insights into KIR2DL4-HLA-G interaction by cryo-EM analysis of recombinant complexes*"
**作者**: Zhang Q, et al.
**摘要**: 通过冷冻电镜解析重组KIR2DL4蛋白与HLA-G复合物的三维结构，揭示了其独特的结合界面及与经典KIR家族成员的结构差异。
4. **文献名称**: *"Recombinant KIR2DL4-Fc fusion protein induces IFN-γ production in uterine NK cells*"
**作者**: Wang X, et al.
**摘要**: 研究构建KIR2DL4-Fc重组融合蛋白，发现其能特异性激活子宫NK细胞分泌IFN-γ，提示其在母胎免疫耐受中的潜在调控机制。
(注：以上文献为示例，实际文献需通过学术数据库检索确认。)
KIR2DL4 (killer cell immunoglobulin-like receptor 2DL4) is a member of the immunoglobulin-like receptor (KIR) family, primarily expressed on natural killer (NK) cells and a subset of T cells. It plays a dual role in immune regulation, interacting with human leukocyte antigen G (HLA-G), a non-classical MHC class I molecule highly expressed in placental trophoblasts and some tumors. This interaction is critical in mediating immune tolerance during pregnancy and modulating NK cell responses in pathological conditions. Structurally, KIR2DL4 features two extracellular immunoglobulin-like domains, a transmembrane region, and a cytoplasmic tail with both inhibitory and activating signaling motifs, enabling context-dependent functional outcomes.
Recombinant KIR2DL4 protein is engineered in vitro to study its biological functions, ligand interactions, and therapeutic potential. Produced using expression systems like mammalian cells or bacteria, the recombinant form retains key structural and functional properties of the native protein. Researchers utilize it to explore mechanisms underlying maternal-fetal tolerance, tumor immune evasion, and autoimmune diseases. For instance, studies show soluble KIR2DL4 can induce NK cell cytokine secretion (e.g., IFN-γ) through endosomal signaling pathways, distinct from conventional surface receptor activation. Its unique ability to bind HLA-G and heparin sulfate proteoglycans has spurred interest in developing diagnostic tools or immunotherapies targeting pregnancy complications, cancer, or chronic inflammation. However, challenges remain in resolving its precise signaling cascades and reconciling conflicting reports about its activating versus inhibitory roles in different microenvironments.
×
